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Comprehensive, patient-tailored, and flexible cancer follow-up is possible through 
digitally-enabled patient-reported outcome measures  
O.C. Lindner1, G. Velikova2, D.P. Stark2 
1. Division of Psychological and Social Medicine, Leeds Institute of Health 
Sciences, School of Medicine, University of Leeds. 
2. Patient-Centred Outcomes Research Group, Leeds Institute of Cancer and 
Pathology, School of Medicine, University of Leeds 
Heathcote et al.1 suggest that follow-up cancer care should go beyond clinical 
recurrence indicators by FRQVLGHULQJSDWLHQWV¶symptoms. This can be done efficiently 
through patient-reported outcome measures (PROMs). They increase quality of life 
and survival2 as cliQLFLDQVDGGUHVVSDWLHQWV¶QHHGV in a tailored manner. 
In aggressive lymphoma more relapses were detected through patient symptoms 
than through physical and biomedical examinations3. The low yield of clinical 
examinations in asymptomatic patients was also demonstrated in germ cell tumours4 
(GCT). 
Digitally-enabled PROMs can facilitate relapse identifications and psychosocial care 
provision for the growing number of follow-up patients. GCT patients in our service 
wanted care that detected recurrence early, holistic monitoring and management of 
treatment effects, with flexibility in timing.  
After treatment, patients enter Standard Follow-up. It involves intensive surveillance 
that reduces treatment intensity/toxicity while ensuring quick access to curative 
treatment when necessary. Clinical investigations (i.e. blood markers, X-rays) and 
symptom assessments are performed during GCT outpatient appointments. Our 
service caters for an average of 1250 appointments/year which have a scheduled 
frequency, based on risk-stratified algorithms5.  
Building upon our cHQWUH¶VH[SHUWLVHLQLQWHJUDWLQJPROMs2 in clinical practice, we 
implemented a Shared Community Follow-up model. Face-to-face appointments are 
replaced by scheduled, online PROMs fed securely LQWRWKHSDWLHQWV¶KRVSLWDOUHFRUG
Patients monitor symptoms, the oncology team monitors their status and acts or 
reassures as needed. When due, patients are reminded to report symptoms online 
and to organise blood and radiological work within a 2-week window at any 
competent provider (i.e. primary care). PROMs and clinical results are interpreted by 
WKHSDWLHQWV¶RQFRORJ\WHDP 
Over two years of implementing Community Follow-up alongside Standard Follow-up 
(2015-2017) we evaluated uptake, safety, and satisfaction in consecutive patients 
using these services. Uptake to Community Follow-up doubled (10% to 21%), online 
PROMs replaced three appointments/patient, non-attendance decreased, and more 
investigations were on time. During evaluation one relapse was identified in each 
service - in Community Follow-up based on tumour markers, in Standard Follow-up 
through self-examination. Treatment commenced within a week for both. Patients 
Manuscript
choosing Community Follow-up were better educated, employed, and lived farther 
from the hospital. Patients were equally satisfied with their follow-up choices. 
Heathcote recognises the challenges of interpreting patient-reported symptoms, 
advocating for patient education. Digitally-enabled PROMs guide this, informing on 
education needs for specific populations.  
However, novel follow-up models warrant testing. Clinical trials and implementation 
research can describe where face-to-face follow-up remains necessary across 
clinical and geographical settings. 
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